ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

DOW JONES NEWSWIRES Merck & Co.'s (MRK) first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth. Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin. Merck has said it expects to seek regulatory approval for five new products this year and in 2013, including potential treatments for osteoporosis, insomnia and a next-generation vaccine against a cancer-causing virus. The drug maker also has been focusing on areas such as hepatitis C and diabetes. Merck reported a profit of $1.74 billion, or 56 cents a share, up from $1.04 billion, or 34 cents, a year earlier. Excluding items such as acquisition-related and restructuring costs, earnings rose to 99 cents from 92 cents. Its March projection was earnings of 95 cents to 98 cents a share, below analysts' expectations at the time. Sales rose 1.3% to $11.73 billion, missing the $11.82 billion forecast from analysts polled by Thomson Reuters. Operating margin rose to 21.4% from 14.9%, reflecting a 14% drop in research and development costs. Pharmaceutical sales grew 2.7% to $10.08 billion. Singulair sales edged up 0.9%, while sales of Vytorin declined 8%. The animal-health business, which includes products for farm animals and pets, posted a 8.3% revenue increase. Sales in the consumer division--which includes over-the-counter allergy medicine Claritin and Coppertone skin-care products--rose 7.2%. Shares closed Thursday at $38.47 and were inactive premarket. The stock is up 2% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/01/201508:14:09Roche looking for collaboration partners in cancer immunotherapies
03/31/201509:01:58Why It's Not Too Late to Buy Agenus, Inc. Stock
03/31/201509:01:58Why It's Not Too Late to Buy Agenus, Inc. Stock
03/31/201508:00:00Syndax & Merck to Collaborate on Immuno-Oncology Study Evaluating...
03/31/201507:07:02The Single Worst Practice of the Drug Industry
03/30/201509:18:40OncoSec Medical Has A Promising Technology
03/30/201506:02:37Berkshire Hathaway Is Terrific - Cramer's Lightning Round (3/27/15)
03/29/201510:02:03Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
03/29/201503:44:43Merck: Buyback Plan Not As Impressive As It Appears
03/28/201514:02:03Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently...
03/27/201509:19:49Ebola vaccine candidates pass safety test in in Liberia trials
03/27/201508:00:00Merck to Hold First-Quarter 2015 Sales and Earnings Conference...
03/27/201507:58:02Is This Tiny Biotech Still a Buy at All-Time Highs?
03/26/201508:30:00Merck Announces Collaboration with the American Diabetes Association...
03/25/201519:09:32Investors Scoop Up Companies' Bonds
03/25/201508:48:22Merck's Dividend Has Recovered From Pre-Recession Problems
03/25/201506:30:55Wall Street Breakfast: Kraft, Heinz Announce Mega Merger
03/24/201517:58:29Merck Increases Buyback Authorization by $10 Billion
03/24/201517:00:00Merck Announces New $10 Billion Share Repurchase Program
03/24/201509:08:25Merck's Keytruda tops Bristol-Myers' Yervoy in melanoma trial

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad